IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.
PATINA supports adding palbociclib to anti-HER2 plus endocrine therapy in HR+/HER2+ disease, and HER2CLIMB-05 validates tucatinib with HP after THP induction. Sequencing trials must address ADC ...
Adding the immune checkpoint inhibitors (ICIs) ipilimumab and nivolumab to percutaneous hepatic perfusion may improve survival outcomes in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results